NCT07456839

A Mutiple-dose Study of IBI3033 in Healthy Participants

A Randomized, Double-blind, Placebo-controlled, Mutiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of IBI3033 in Healthy Participants

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (estimated)
• Sponsor: Innovent Biologics (Suzhou) Co. Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

This is a Phase 1, randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3033 in Chinese healthy participants. The entire trial cycle includes a 4-week screening period, 8-week treatment period and 8-week follow-up period.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	Placebo	Participants in placebo group will receive placebo SC.
DRUG	IBI3033	Participants in IBI3033 group will receive multiple doses of IBI3033 SC at the protocol specified dose level and time points.

Timeline

• Start date: 2026-03-24
• Primary completion: 2026-09-30
• Completion: 2026-11-13
• First posted: 2026-03-09
• Last updated: 2026-03-09

Locations

1 site across 1 country: China